Adaptive Biotechnologies director Griffin sells $214,130 in stock

Michelle Renee Griffin sold 15,394 ADPT shares on March 11, 2026 at a $13.91 weighted-average price for $214,130, leaving her with 15,625 shares. Adaptive Biotechnologies beat Q4 2025 estimates with EPS of -$0.09 vs -$0.18 and revenue of $71.7M vs $59.33M; MRD business growth was 54% YoY in Q4 and 46% for the full year. TD Cowen raised its price target to $21 from $20 and BTIG to $22 from $21, while Piper Sandler reiterated Overweight and expects clonoSEQ volume growth >30%. The stock trades at $13.17 (flagged as overvalued on InvestingPro) and has shown volatility (down 11% last week, +81% over the last year).

Analysis

Adaptive’s MRD momentum is likely to drive asymmetric outcomes: recurring, test-based revenue can compress revenue volatility and deliver high incremental margins as fixed lab capacity is leveraged, but the path from superior growth to durable free cash flow depends on two levers — sustained volume growth beyond early-adopter cohorts and successful payer coverage expansion. If both hold, shareholders see margin expansion and multiple re-rating over 6–18 months; if coverage or mix shifts stall, the multiple could quickly derate given current expectations priced into the equity.

Competitive dynamics favor incumbents with scale in clinical MRD workflows because pharma trial adoption and diagnostic lab partnerships create high switching costs; however, ctDNA/NGS competitors can compete on pricing or bundled services, creating a squeeze on per-test economics. The real second-order winners are clinical lab service providers and CROs that integrate MRD endpoints into trial protocols — they capture incremental margin and can lock in long-term revenue streams even if the diagnostic vendor base fragments.

Key risks cluster around reimbursement decisions and potential dilution. Payer coverage timelines are binary and lumpy (decision windows often 6–18 months), and a single negative coverage decision or disappointing commercial cadence can remove the premium valuation nearly overnight. Near-term catalysts to monitor: quarterly volume cadence, payer announcements, and any pharma trial readouts that reference MRD endpoints — each can reprice risk within weeks rather than quarters.

Key Decisions for Investors

• Selective pair trade (6–12 months): Long ADPT equity (small allocation) paired with short NTRA or GH proportional to expected MRD share shifts to isolate company-specific execution risk. Target +35% on pair if ADPT sustains better-than-peer commercial traction; cut pair if relative performance slips >20% over a rolling 3-month window.
• Defined-risk options (9–12 months): Buy ADPT 12-month call debit spread to capture upside from continued MRD adoption while limiting theta — size as 1–2% notional. Reward scenario: >2x if next 2 quarters beat consensus on volumes; downside limited to premium paid (~100% of option cost).
• Event-driven short (3–6 months): If near-term commercial cadence misses or a major payer issues restrictive coverage, initiate tactical short via puts or borrowable shares sized to risk appetite — aim for 30–50% downside capture from re-rating. Use tight stops and scale out on rallies of 15–25%.
• Avoid outright long conviction until a) multiple quarters of sustained margin expansion are reported and b) clear national payer wins are posted. Re-evaluate long after 2 consecutive quarters of compounding volume + visible pricing stability (6–12 months horizon).